PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.24%
Revenue growth under 50% of MRVL's 40.11%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
47.23%
Gross profit growth 1.25-1.5x MRVL's 41.63%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
83.58%
EBIT growth above 1.5x MRVL's 55.44%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
83.58%
Operating income growth above 1.5x MRVL's 55.44%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
67.24%
Net income growth 1.25-1.5x MRVL's 56.19%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
72.41%
EPS growth similar to MRVL's 74.44%. Walter Schloss would assume both have parallel share structures and profit trends.
72.41%
Similar diluted EPS growth to MRVL's 74.44%. Walter Schloss might see standard sector or cyclical influences on both firms.
18.75%
Share reduction more than 1.5x MRVL's 69.81%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
18.75%
Diluted share reduction more than 1.5x MRVL's 69.81%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
-13.45%
Dividend reduction while MRVL stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-62.05%
Negative OCF growth while MRVL is at 346.70%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-67.65%
Negative FCF growth while MRVL is at 254.51%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-45.13%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-35.18%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-24.61%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
1782.46%
10Y OCF/share CAGR above 1.5x MRVL's 20.30%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-18.33%
Negative 5Y OCF/share CAGR while MRVL is at 20.30%. Joel Greenblatt would question the firm’s operational model or cost structure.
14.77%
3Y OCF/share CAGR at 50-75% of MRVL's 20.30%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-148.33%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-123.65%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-112.54%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
216.59%
Below 50% of MRVL's 6767.83%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
124.69%
Below 50% of MRVL's 6767.83%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
49.26%
Below 50% of MRVL's 6767.83%. Michael Burry suspects a serious short-term disadvantage in building book value.
-27.60%
Cut dividends over 10 years while MRVL stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-7.16%
Negative 5Y dividend/share CAGR while MRVL stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-5.66%
Negative near-term dividend growth while MRVL invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
4.26%
AR growth well above MRVL's 1.73%. Michael Burry fears inflated revenue or higher default risk in the near future.
2.26%
We show growth while MRVL is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-1.53%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-16.01%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
0.24%
We have some new debt while MRVL reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
1.57%
R&D dropping or stable vs. MRVL's 70.25%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-11.96%
We cut SG&A while MRVL invests at 52.56%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.